Walgreens Boots Alliance Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de Walgreens Boots Alliance han disminuido a una tasa media anual de -41.4%, mientras que en la industria Consumer Retailing los beneficios crecieron en un 21.4% anualmente. Los ingresos han ido creciendo a una tasa media de 1.9% al año.

Información clave

-41.4%

Tasa de crecimiento de los beneficios

-40.3%

Tasa de crecimiento del BPA

Crecimiento de la industria Consumer Retailing	12.4%
Tasa de crecimiento de los ingresos	1.9%
Rentabilidad financiera	-83.7%
Margen neto	-4.2%
Última actualización de beneficios	29 Feb 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Walgreens Boots Alliance. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

BASE:WBA Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
29 Feb 24	144,597	-6,037	25,226
30 Nov 23	142,406	574	24,880
31 Aug 23	139,081	-3,080	24,860
31 May 23	136,108	-3,315	25,073
28 Feb 23	133,291	-3,144	24,502
30 Nov 22	132,184	-2,964	24,912
31 Aug 22	132,703	4,337	24,627
31 May 22	134,516	5,111	25,925
28 Feb 22	135,948	5,926	25,542
30 Nov 21	134,972	5,965	24,865
31 Aug 21	132,509	1,994	23,798
31 May 21	128,617	1,972	23,305
28 Feb 21	124,952	-926	23,194
30 Nov 20	123,509	-981	23,052
31 Aug 20	121,982	179	22,836
31 May 20	125,566	519	23,676
29 Feb 20	129,792	3,339	24,269
30 Nov 19	132,984	3,628	24,521
31 Aug 19	120,074	3,816	23,183
31 May 19	136,354	4,817	25,135
28 Feb 19	136,097	5,133	25,112
30 Nov 18	134,590	5,326	25,065
31 Aug 18	131,537	5,024	24,638
31 May 18	128,244	4,314	23,745
28 Feb 18	124,028	4,134	23,520
30 Nov 17	120,453	3,845	23,067
31 Aug 17	118,214	4,078	23,618
31 May 17	116,701	4,306	23,115
28 Feb 17	116,081	4,247	23,046
30 Nov 16	116,819	4,117	23,302
31 Aug 16	117,351	4,173	23,425
31 May 16	117,237	3,169	23,409
29 Feb 16	116,534	3,368	23,433
30 Nov 15	112,923	4,480	22,996
31 Aug 15	103,444	4,220	21,669
31 May 15	93,979	3,973	20,224
28 Feb 15	84,585	3,385	18,611
30 Nov 14	77,617	2,059	17,661
31 Aug 14	76,392	1,932	17,691
31 May 14	75,276	2,810	17,684
28 Feb 14	74,188	2,720	17,579
30 Nov 13	73,230	2,760	17,473
31 Aug 13	72,217	2,548	17,470
31 May 13	71,349	2,146	17,393

Ingresos de calidad: WBA actualmente no es rentable.

Margen de beneficios creciente: WBA actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: WBA no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 41.4% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de WBA en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: WBA no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Consumer Retailing (7.6%).

Rentabilidad financiera

Alta ROE: WBA tiene una rentabilidad financiera negativa (-83.68%), ya que actualmente no es rentable.

Walgreens Boots Alliance Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022

Walgreens Boots Alliance, Inc. to Report Q3, 2022 Results on Jun 30, 2022

Recent updates

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on June 12, 2024

Wisner Baum Files Multiple Class Actions Alleging Several Companies Sold Benzoyl Peroxide Acne Products Without Warning Consumers That They Contain Unsafe Levels of Benzene, a Potent Human Carcinogen

Walgreens Boots Alliance, Inc. to Report Q2, 2024 Results on Mar 28, 2024

Walgreens Boots Alliance, Inc. Names Lanesha Minnix as Executive Vice President and Global Chief Legal Officer

Walgreens Boots Alliance, Inc. Announces Executive Changes

Walgreens Boots Alliance, Inc. Elects Robert L. Huffines to Board of Directors

Walgreens Reportedly Explores $4 Billion-Plus Sale of Shields Health

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on March 12, 2024

The Shareholder Commons, Inc Files a Notice of Exempt Solicitation to Walgreens Boots Alliance, Inc

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 25, 2024

Walgreens Boots Alliance, Inc. to Report Q1, 2024 Results on Jan 04, 2024

Walgreens Boots Alliance Names Neal Sample Executive Vice President and Chief Information Officer

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2023

Walgreens Boots Alliance, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Walgreens Boots Alliance, Inc. Appoints Tim Wentworth as Chief Executive Officer, Effective October 23, 2023

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from S&P 100

Dicello Levitt Files Lawsuit Against Kenvue, Procter & Gamble, Glaxosmithkline, and Walgreens

Walgreens Boots Alliance, Inc. Announces CEO Changes

Walgreens Boots Alliance, Inc. Announces CEO Changes

Walgreens Boots Alliance, Inc. Announces Departure of James Kehoe as Executive Vice President

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on September 12, 2023

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire 120 pharmacies in Texas, Louisiana and Arkansas from Brookshire Grocery Company.

An unknown buyer acquired 6.004471% stake in Option Care Health, Inc. (NasdaqGS:OPCH) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for approximately $330 million.

Walgreens Boots Alliance, Inc. to Report Q3, 2023 Results on Jun 27, 2023

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 10, 2023

Walgreens Reportedly Weighs $2 Billion Sale of Pharmacy Automation Unit

Walgreens Boots Alliance, Inc. Provides Sales Guidance for Fiscal 2023

Walgreens Boots Alliance, Inc. to Report Q1, 2023 Results on Jan 05, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc., Annual General Meeting, Jan 26, 2023

Walgreens Boots Alliance, Inc. Announces Resignation of William Foote, the Board Lead Independent Director

Walgreens Boots Alliance, Inc. Declares Quarterly Dividend, Payable on December 12, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into a definitive agreement to acquire remaining 45% stake in CareCentrix, Inc. for approximately $390 million.

John Standley to Leave as Executive Vice President of Walgreens Boots Alliance, Inc. on November 1, 2022

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) entered into an agreement to acquire additional 30% stake in Shields Specialty Pharmacy Holdings, LLC from Welsh, Carson, Anderson & Stowe, Jack Shields & others for approximately $1.4 billion.

Walgreens Boots Alliance, Inc. to Report Q4, 2022 Results on Oct 13, 2022

Walgreens Boots Alliance, Inc. Announces Executive Appointments

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) completed the acquisition of a 55% stake in CareCentrix, Inc.

Walgreens Boots Alliance, Inc. Names Alethia Jackson Senior Vice President, ESG and Chief DEI Officer

Walgreens Boots Alliance, Inc. Announces Resignation of David J. Brailer as Member of the Board of Directors

Jnd Legal Administration Announces A Class Action Lawsuit in the U.S. District Court for the District of Arizona Against Defendants Theranos, Inc., Walgreens Boots Alliance, Inc. and Walgreen Arizona Drug Company

Walgreens Boots Alliance Increases Quarterly Dividend, Payable September 9, 2022

Walgreens Boots Alliance Concludes Strategic Review and Decides to Retain Ownership of Its Successful Boots Business

Walgreens Launches Clinical Trial Business to Address Industrywide Access and Diversity Challenges and Redefine Patient Experience

Walgreens Boots Alliance, Inc. to Report Q3, 2022 Results on Jun 30, 2022

Walgreens Reportedly Gives A Few Extra Days for Bidders to Firm Up Offers

An unknown buyer acquired 2.9% stake in AmerisourceBergen Corporation (NYSE:ABC) from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for $900 million.

Walgreens Boots Alliance, Inc. Reaches Opioid Settlement with State of Florida

Walgreens Reportedly Sets Deadline for Bids in Boots Auction

Reliance Industries Reportedly Studying Possible Bid for Walgreens' Boots Chain

Private Equity Giant Reportedly Abandons Boots Takeover

Walgreens Boots Alliance, Inc. Appoints Steven J. Shulman to Its Board of Directors

Walgreens Boots Alliance Declares Quarterly Dividend, Payable on March 11, 2022

Bain and CVC Reportedly to Team Up for Boots Bid

Oak Street Real Estate Capital, LLC acquired 1.68-acre property at 3600 Winter Garden Vineland Road in Winter Garden from Walgreens Boots Alliance, Inc. (NasdaqGS:WBA) for $5.2 million.

PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August

Walgreens Boots Alliance, Inc.(NasdaqGS:WBA) dropped from Russell 1000 Defensive Index

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta